Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):473.
doi: 10.21037/atm.2017.09.28.

Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not

Thomas F Heston  1   2 , Anndres H Olson  1 , Nicholas R Randall  1
Affiliations
Editorial

Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not

Thomas F Heston et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Neal B, et al. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605608 Clinical Trial.

References

    1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8. 10.1001/jama.1979.03290450033020 - DOI - PubMed
    1. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-20. 10.7326/0003-4819-141-6-200409210-00006 - DOI - PubMed
    1. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015;1358:28-43. 10.1111/nyas.12852 - DOI - PubMed
    1. Rosenstock J, Chuck L, González-Ortiz M, et al. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. Diabetes Care 2016;39:353-62. 10.2337/dc15-1736 - DOI - PubMed
    1. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67:1267-82. 10.1111/ijcp.12322 - DOI - PMC - PubMed

LinkOut - more resources